Villers-lès-Nancy, August 9 2012 - 07.00 am (CET)
PRESS RELEASE
Half year turnover (June 30 2012): + 9.6%
| M€ | 2011 | 2012 | Variation |
| Q1 | 25.20 | 26.74 | + 6.1% |
| Q2 | 25.03 | 28.29 | + 13% |
| Total 1st half year | 50.23 | 55.03 | + 9.6% |
After a first quarter for 2012 in keeping with expectations, the PHARMAGEST Group has produced an excellent second quarter with a rise of 13% compared to the second quarter of 2011, bringing turnover for the first half year to 55.03 M€ at 30 June 2012, an increase of 9.6% compared to 30 June 2011.
Note on activity:
* Pharmacy France business, with turnover of 45.60 M€ for the first half year 2012, up 11.1% compared to the first half year 2011, maintains excellent commercial growth with increases in all revenues:
- Configurations sales +14.3%
- Recurring revenue (maintenance and data bases): +7.1%
- Sales of products developed by Pharmagest Interactive: +6.1%
The Pharmacy France business represents 82.9% of the Group's turnover for the first half year 2012.
* Pharmacy business in Belgium and Luxembourg is stable (1.60 M€ of turnover, an increase of 0.35%) over the first half year 2012. The 13.2% increase in orders is only partially reflected in Q2 turnover which is up 7.3% and is a good sign that this positive trend will continue in the months to come.
At June 30 2012, business from Belgium and Luxembourg contributed to the Group's turnover at a level of 2.9%.
* In a context of budgetary restrictions in the Pharmaceutical Industry, the Laboratories business posts turnover of 5.97 M€, a slight fall (-3%) compared to June 30 2011. The decline is however limited to the low margin "Communication services", the classic business enjoying a growth level of +1.5%.
The Laboratories business represents 10.8% of the Group's half year turnover.
* The Care Homes business continues its strong growth. Its turnover of 1.76 M€, an increase of 22.8%, benefits from the excellent level of recurring business (+ 34.3%) as well as sales of licenses (+29 %), which make up 58% of this business's turnover.
The Care Homes business represents 3.2% of the Group's turnover at 30 June 2012.
* The new e-Health business, created during Q1 2012, has not yet contributed to the PHARMAGEST Group's turnover in any significant way.
Prospects:
The Group calmly anticipates a good performance of growth in its businesses over the second half year of 2012.
Furthermore, it will continue its research and development work to help the pharmacist, but will also remain alert to external growth opportunities in France and internationally in the fields of innovative technologies, linked to Health.
Financial timetable:
- Publication of half year results 29 August 2012
- Meeting for Presentation of half year results in Paris 11 September 2012
- MidCap Event in Paris 24 and 25 September 2012
- Publication of Q3 turnover 15 November 2012
About the PHARMAGEST Group:
The PHARMAGEST Group is the French leader in computer systems for pharmacies, with a 43.5% share of the market, 9,800 clients and more than 700 employees. Since September 2007, the PHARMAGEST Group has also been present in Northern Europe with a 12% market share in Belgium and Luxembourg through its subsidiary SABCO.
As a privileged partner to pharmacists for almost 30 years now, the PHARMAGEST Group designs innovative computer solutions for pharmacies and is developing a high potential E-Business E-Media activity intended for laboratories.
The PHARMAGEST Group is also developing previously unpublished software solutions for Retirement Homes (Care Homes and day centres for the elderly), through its subsidiary MALTA INFORMATIQUE.
The first Logiciel de Gestion à Portail Intégré (Integrated Portal Management Software - LGPI Global Services®), creator of value for the patient, pharmacist and laboratory, dynamises sales, optimises purchases and enriches advice to the patient. It is also the first permanent impact medium for pharmacies, supplying laboratories with direct communication towards the pharmacist and his patients.
Listed on the NYSE Euronext Paris(TM) - Compartment C
Indices CAC ® SMALL90 and CAC ® All-Tradable by inclusion
ISIN: FR 0000077687 - Reuters: PHA.PA - Bloomberg: - PMGI FP
Find out the latest news from the group at www.pharmagest.com
CONTACTS
Chairman of the Board of Directors: Thierry CHAPUSOT
Managing Director: Dominique PAUTRAT
Tel. 03 83 15 90 67 - dominique.pautrat@pharmagest.com
Analyst and Investor Relations: Administrative and Financial Director: Jean-Yves SAMSON
Tel. 03 83 15 90 67 - jean-yves.samson@pharmagest.com
Press Relations: FIN'EXTENSO Isabelle APRILE
Tel. 01 39 97 61 22 - i.aprile@finextenso.fr
